Peptide therapy stories

Jul 24, 2026

FDA Advisory Panel Recommends Easing Restrictions on Unapproved Peptides Despite Agency Scientists' Concerns

Outside advisers to the U.S. Food and Drug Administration narrowly voted to recommend broader access to several unapproved peptides popular in wellness circles, backing a push by HHS Secretary Robert F. Kennedy Jr. despite objections from FDA career scientists about limited safety data and potential conflicts of interest among panelists.

Jul 24, 20268 sources

Jul 22, 2026

FDA panel votes to allow compounding of peptide BPC-157

FDA advisory panel voted to place peptide BPC-157 on a list allowing broader pharmacy compounding, the first of seven peptides under review. The decision supports HHS Secretary RFK Jr.'s push to expand access to these compounds.

Jul 22, 20266 sources

Top claims

▪Food and Drug Administration official Russell Wesdyk stated that the chemical composition of peptides labeled with the same name varies considerably, presenting a foundational challenge for establishing quality standards.
▪Health and Human Services Secretary Robert F. Kennedy Jr., who has publicly supported peptide therapies, appointed the new panel members who voted to ease the peptide compounding restrictions.
▪The Food and Drug Administration Pharmacy Compounding Advisory Committee voted to recommend compounding for BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax, while voting against emideltide.

People involved

Robert F. Kennedy Jr.

Subtopics

Biohacking & optimization2 Supplement regulation2 BPC-1571 Drug Approval and Clinical Trials1 FDA regulatory process1 Public healthcare1 US health policy & drug pricing1

Related timelines